WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H408124
CAS#: 644981-35-1
Description: Val-Cit-PAB-MMAE is a MMAE derivative with a cleavable linker, which is useful to make MMAE conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE. MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
Hodoodo Cat#: H408124
Name: Val-Cit-PAB-MMAE
CAS#: 644981-35-1
Chemical Formula: C58H94N10O12
Exact Mass: 1,122.71
Molecular Weight: 1,123.448
Elemental Analysis: C, 62.01; H, 8.43; N, 12.47; O, 17.09
Synonym: Val-Cit-PAB-MMAE; MMAE ADC conjugate; N-PM-0008; N-PM 0008; N-PM0008; NPM-0008; NPM 0008; NPM0008;
IUPAC/Chemical Name: 4-((S)-2-((S)-2-amino-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
InChi Key: WZEAGSMYTVSXQA-XZZQEHRXSA-N
InChi Code: InChI=1S/C58H94N10O12/c1-15-36(8)49(44(78-13)31-45(69)68-30-20-24-43(68)51(79-14)37(9)52(71)62-38(10)50(70)40-21-17-16-18-22-40)66(11)56(75)47(34(4)5)65-55(74)48(35(6)7)67(12)58(77)80-32-39-25-27-41(28-26-39)63-53(72)42(23-19-29-61-57(60)76)64-54(73)46(59)33(2)3/h16-18,21-22,25-28,33-38,42-44,46-51,70H,15,19-20,23-24,29-32,59H2,1-14H3,(H,62,71)(H,63,72)(H,64,73)(H,65,74)(H3,60,61,76)/t36-,37+,38+,42-,43-,44+,46-,47-,48-,49-,50+,51+/m0/s1
SMILES Code: CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)N)=O)=O)C=C3)=O)C)=O)=O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC and potent tubulin inhibitor MMAE (HY-15162). |
| In vitro activity: | TBD |
| In vivo activity: | TBD |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 50.0 | 44.50 |
The following data is based on the product molecular weight 1,123.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | TBD |
| In vitro protocol: | TBD |
| In vivo protocol: | TBD |
1: Samineni D, Ding H, Ma F, Shi R, Lu D, Miles D, Mao J, Li C, Jin J, Wright M, Girish S, Chen Y. Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials. J Clin Pharmacol. 2020 Oct;60 Suppl 1:S120-S131. doi: 10.1002/jcph.1718. PMID: 33205435.
2: Olatunji FP, Herman JW, Kesic BN, Olabode D, Berkman CE. A click-ready pH- triggered phosphoramidate-based linker for controlled release of monomethyl auristatin E. Tetrahedron Lett. 2020 Oct 8;61(41):152398. doi: 10.1016/j.tetlet.2020.152398. Epub 2020 Aug 29. PMID: 33191958; PMCID: PMC7665082.
3: Powell Gray B, Song X, Hsu DS, Kratschmer C, Levy M, Barry AP, Sullenger BA. An Aptamer for Broad Cancer Targeting and Therapy. Cancers (Basel). 2020 Oct 31;12(11):E3217. doi: 10.3390/cancers12113217. PMID: 33142831.
4: Amatore F, Ortonne N, Lopez M, Orlanducci F, Castellano R, Ingen-Housz-Oro S, De Croos A, Salvado C, Gorvel L, Goubard A, Collette Y, Bouabdallah R, Schiano JM, Bonnet N, Grob JJ, Gaulard P, Bagot M, Bensussan A, Berbis P, Olive D. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Adv. 2020 Oct 27;4(20):5203-5214. doi: 10.1182/bloodadvances.2020002395. PMID: 33095875; PMCID: PMC7594390.
5: Pan D, Tang Y, Tong J, Xie C, Chen J, Feng C, Hwu P, Huang W, Zhou D. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer. Cancer Med. 2020 Oct 20. doi: 10.1002/cam4.3554. Epub ahead of print. PMID: 33084221.
6: Jendryczko K, Chudzian J, Skinder N, Opaliński Ł, Rzeszótko J, Wiedlocha A, Otlewski J, Szlachcic A. FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1. Cancers (Basel). 2020 Oct 15;12(10):2992. doi: 10.3390/cancers12102992. PMID: 33076489; PMCID: PMC7602595.
7: Hartmann RW, Fahrner R, Shevshenko D, Fyrknäs M, Larsson R, Lehmann F, Odell LR. Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing. ChemMedChem. 2020 Oct 16. doi: 10.1002/cmdc.202000497. Epub ahead of print. PMID: 33063934.
8: Slemmons KK, Mukherjee S, Meltzer P, Purcell JW, Helman LJ. LRRC15 antibody- drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. Pediatr Blood Cancer. 2020 Oct 16:e28771. doi: 10.1002/pbc.28771. Epub ahead of print. PMID: 33063919.
9: Huang R, Sheng Y, Wei D, Lu W, Xu Z, Chen H, Jiang B. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates. Bioorg Med Chem. 2020 Oct 6;28(23):115793. doi: 10.1016/j.bmc.2020.115793. Epub ahead of print. PMID: 33039798.
10: Wang Q, Gavin W, Masiello N, Tran KB, Laible G, Shepherd PR. Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models. Biotechnol Rep (Amst). 2020 Sep 22;28:e00533. doi: 10.1016/j.btre.2020.e00533. PMID: 33024714; PMCID: PMC7528048.
11: Halford Z, Anderson MK, Clark MD. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2020 Sep 18:1060028020960402. doi: 10.1177/1060028020960402. Epub ahead of print. PMID: 32945172.
12: Jin R, Liu L, Xing Y, Meng T, Ma L, Pei J, Cong Y, Zhang X, Ren Z, Wang X, Shen J, Yu K. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune- Effector Function. Mol Cancer Ther. 2020 Sep 17. doi: 10.1158/1535-7163.MCT-20-0076. Epub ahead of print. PMID: 32943546.
13: Wang S, Wen H, Fei W, Zhao Y, Feng Y, Kuang L, Wang M, Wu M. Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models. Am J Cancer Res. 2020 Aug 1;10(8):2387-2408. PMID: 32905508; PMCID: PMC7471348.
14: Yaghoubi S, Gharibi T, Karimi MH, Sadeqi Nezhad M, Seifalian A, Tavakkol R, Bagheri N, Dezhkam A, Abdollahpour-Alitappeh M. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). Breast Cancer. 2020 Sep 5. doi: 10.1007/s12282-020-01153-5. Epub ahead of print. PMID: 32889587.
15: Anderson MG, Falls HD, Mitten MJ, Oleksijew A, Vaidya KS, Boghaert ER, Gao W, Palma JP, Cao D, Chia PL, John T, Gan HK, Scott AM, Reilly EB. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody- Drug Conjugate. Mol Cancer Ther. 2020 Oct;19(10):2117-2125. doi: 10.1158/1535-7163.MCT-20-0149. Epub 2020 Aug 26. PMID: 32847977.
16: Liu X, Mohanty RP, Maier EY, Peng X, Wulfe S, Looney AP, Aung KL, Ghosh D. Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy. J Control Release. 2020 Aug 14;328:1-12. doi: 10.1016/j.jconrel.2020.08.015. Epub ahead of print. PMID: 32798638.
17: Châtre R, Lange J, Péraudeau E, Poinot P, Lerondel S, Le Pape A, Clarhaut J, Renoux B, Papot S. In vivo synthesis of triple-loaded albumin conjugate for efficient targeted cancer chemotherapy. J Control Release. 2020 Nov 10;327:19-25. doi: 10.1016/j.jconrel.2020.08.008. Epub 2020 Aug 7. PMID: 32777236.
18: Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359. doi: 10.1007/s00280-020-04119-8. Epub 2020 Aug 8. PMID: 32770353; PMCID: PMC7478950.
19: Lu T, Gibiansky L, Li X, Li C, Shi R, Agarwal P, Hirata J, Miles D, Chanu P, Girish S, Jin JY, Lu D. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2020 Dec;61(12):2905-2914. doi: 10.1080/10428194.2020.1795154. Epub 2020 Jul 24. PMID: 32705923.
20: Bourbon E, Salles G. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs. 2020 Oct;29(10):1079-1088. doi: 10.1080/13543784.2020.1800638. Epub 2020 Aug 12. PMID: 32700972.
